Rein Therapeutics (RNTX, Financial) has announced a significant milestone with the U.S. Patent and Trademark Office granting two new patents focused on its flagship product candidate, LTI-03. These patents, issued on April 22, 2025, reinforce the company's intellectual property portfolio for a groundbreaking synthetic peptide therapy.
The patents, numbered U.S. Patent No. 12,280,088 and U.S. Patent No. 12,280,089, are both titled "Dry Powder Formulation of Caveolin-1 Peptides and Methods of Use Thereof." They pertain to the dry powder inhalation formulation of LTI-03 and its application in treating a range of lung ailments, such as interstitial lung disease, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory or fibrotic lung disorders.
LTI-03 is distinguished by its dual mechanism of action, which not only promotes the survival of alveolar epithelial cells but also inhibits profibrotic signaling. This innovative approach positions LTI-03 as a promising therapy for several debilitating lung conditions, offering hope for improved management and outcomes for patients.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for Rein Therapeutics Inc (RNTX, Financial) is $13.00 with a high estimate of $19.00 and a low estimate of $7.00. The average target implies an upside of 602.70% from the current price of $1.85. More detailed estimate data can be found on the Rein Therapeutics Inc (RNTX) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, Rein Therapeutics Inc's (RNTX, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
